Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77.1M
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
39.5M
-
Shares change
-
-1.54M
-
Total reported value, excl. options
-
$1.05B
-
Value change
-
-$66.7M
-
Number of buys
-
69
-
Number of sells
-
-30
-
Price
-
$26.53
Significant Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q2 2021
117 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2021.
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.5M shares
of 77.1M outstanding shares and own 51.23% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (4.05M shares), TRV GP III, LLC (3.42M shares), Redmile Group, LLC (3.19M shares), BAKER BROS. ADVISORS LP (2.45M shares), BlackRock Inc. (2.09M shares), EcoR1 Capital, LLC (1.97M shares), STATE STREET CORP (1.86M shares), VANGUARD GROUP INC (1.47M shares), WELLINGTON MANAGEMENT GROUP LLP (1.39M shares), and Bain Capital Life Sciences Investors, LLC (1.28M shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.